PROANGIOGENNYE FAKTORY V SYVOROTKE KROVI I OPUKhOLI BOL'NYKh RAKOM POChKI
- Authors: Mushtenko VV1, Glybin PV1, Kolpakov AV1, Morozov AA1
-
Affiliations:
- Issue: Vol 16, No 4 (2016)
- Pages: 108-109
- Section: Articles
- Published: 15.12.2016
- URL: https://journals.eco-vector.com/MAJ/article/view/9627
- DOI: https://doi.org/10.17816/MAJ164108-109
- ID: 9627
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
References
- Folkman J. Antiangiogenesis: new concept for therapy of solid tumors // Ann. Surg.- 1972.- Vol. 175, № 3.- P. 409-416.
- Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors // Nat. Med.- 2003.- Vol. 9, № 6.- P. 669-676.
- Welsh S. J., Fife K. Pazopanib for the treatment of renal cell carcinoma // Future Oncol.- 2015.- Vol. 11, № 8.- P. 1169-1179.
- Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis / Iacovelli R., Sternberg C. N., Porta C., Verzoni E., de Braud F., Escudier B., Procopio G. // Curr. Drug Targets.- 2015.- Vol. 16, № 2.- P. 164-170.
- Rini B. I., Small E. J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma // J. Clin. Oncol.- 2005.- Vol. 23, № 5.- P. 1028-1043.
Supplementary files
![](/img/style/loading.gif)